{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T16:20:40Z","timestamp":1776356440305,"version":"3.51.2"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Secukinumab, an interleukin-17A (IL-17A) inhibitor, has demonstrated significant efficacy in treating moderate-to-severe plaque psoriasis. Achieving complete skin clearance (PASI 100) is the ideal therapeutic goal. However, individual responses vary, and tools to accurately predict PASI 100 response in real-world settings are lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective study, we analyzed data from 11,134 psoriasis patients who were treated with secukinumab for 3\u202fmonths. The dataset was randomly split into training (70%) and testing (30%) sets. Univariate analysis and LASSO regression were used for feature selection. Eight machine learning algorithms, including Random Forest, LightGBM, and Logistic Regression, were developed to predict treatment response. Model performance was evaluated using the Area Under the Receiver Operating Characteristic Curve (AUC). SHapley Additive exPlanations (SHAP) analysis was employed to interpret the optimal model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 4,593 (41.25%) patients achieved PASI 100 response. The factors of Disease duration, BMI, bBSA, bPASI, bDLQI, Gender, bIGA, Education background, Job status, Comorbidity, Family history, Drug allergy history, Disease situation, Traditional systemic therapy, Medical insurance, Disease status and Biologic usage status were significantly associated with PASI 100 response (all\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.05), while others not. LASSO regression identified 5 key predictors, including Gender, bIGA, bBSA, bPASI and bDLQI. Among the algorithms, Random Forest (training AUC\u202f=\u202f0.879, testing AUC\u202f=\u202f0.757) and LightGBM (training AUC\u202f=\u202f0.834, testing AUC\u202f=\u202f0.761) demonstrated the best performance in those machine learning algorithms. SHAP analysis revealed that gender and baseline disease severity indicators (bIGA, bBSA, bPASI and bDLQI) were important predictors.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We successfully developed Random Forest and LightGBM-based prediction model for PASI100 response to secukinumab with moderate discriminative ability. Baseline disease severity emerged as the dominant predictor of complete skin clearance. These findings provide evidence-based support for personalized treatment goal setting and patient selection in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1764025","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T12:41:00Z","timestamp":1772196060000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Machine learning-based prediction of PASI100 response to secukinumab in patients with psoriasis: a real-world study with SHAP interpretability analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Fengming","family":"Hu","sequence":"first","affiliation":[{"name":"Dermatology Hospital of Jiangxi Province","place":["Nanchang, China"]},{"name":"The Affiliated Dermatology Hospital of Nanchang University","place":["Nanchang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Gong","sequence":"additional","affiliation":[{"name":"Dermatology Hospital of Jiangxi Province","place":["Nanchang, China"]},{"name":"The Affiliated Dermatology Hospital of Nanchang University","place":["Nanchang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxin","family":"Li","sequence":"additional","affiliation":[{"name":"School of Public Health and Health Management, Gannan Medical University","place":["Ganzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohua","family":"Tao","sequence":"additional","affiliation":[{"name":"Dermatology Hospital of Jiangxi Province","place":["Nanchang, China"]},{"name":"The Affiliated Dermatology Hospital of Nanchang University","place":["Nanchang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihua","family":"Zhang","sequence":"additional","affiliation":[{"name":"Dermatology Hospital of Jiangxi Province","place":["Nanchang, China"]},{"name":"The Affiliated Dermatology Hospital of Nanchang University","place":["Nanchang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The immunologic role of Il-17 in psoriasis and psoriatic arthritis pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis\u2014results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/bjd.13348","article-title":"Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (feature)","volume":"172","author":"Blauvelt","year":"2015","journal-title":"Br J Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/jdv.14878","article-title":"Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (sculpture extension study)","volume":"32","author":"Bissonnette","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jaad.2016.03.026","article-title":"Clinical meaningfulness of complete skin clearance in psoriasis","volume":"75","author":"Strober","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/jdv.12817","article-title":"Pasi90 response: the new standard in therapeutic efficacy for psoriasis","volume":"29","author":"Puig","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/jid.2013.326","article-title":"Heterogeneity of response to biologic treatment: perspective for psoriasis","volume":"134","author":"Edson-Heredia","year":"2014","journal-title":"J Invest Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/bjd.17738","article-title":"Factors predicting persistence of biologic drugs in psoriasis: a systematic review and meta-analysis","volume":"181","author":"Mourad","year":"2019","journal-title":"Br J Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/bjd.12663","article-title":"Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: Meta-analysis of randomized controlled trials","volume":"170","author":"Schmitt","year":"2014","journal-title":"Br J Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1111\/jdv.13354","article-title":"European S3-guidelines on the systemic treatment of psoriasis vulgaris--update 2015--short version--Edf in cooperation with Eadv and Ipc","volume":"29","author":"Nast","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1056\/NEJMra1814259","article-title":"Machine learning in medicine","volume":"380","author":"Rajkomar","year":"2019","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nature21056","article-title":"Dermatologist-level classification of skin Cancer with deep neural networks","volume":"542","author":"Esteva","year":"2017","journal-title":"Nature"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/bjd.18880","article-title":"What is Ai? Applications of artificial intelligence to dermatology","volume":"183","author":"Du-Harpur","year":"2020","journal-title":"Br J Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s42256-019-0048-x","article-title":"Stop explaining black box machine learning models for high stakes decisions and use interpretable models instead","volume":"1","author":"Rudin","year":"2019","journal-title":"Nat Mach Intell"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1714792","DOI":"10.3389\/fmed.2025.1714792","article-title":"A shap-interpretable machine learning framework for predicting delayed discharge in ambulatory total knee arthroplasty: comparative validation of 14 models","volume":"12","author":"Feng","year":"2025","journal-title":"Front Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1615950","DOI":"10.3389\/fmed.2025.1615950","article-title":"Shap combined with machine learning to predict mortality risk in maintenance hemodialysis patients: a retrospective study","volume":"12","author":"Shu","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2340\/00015555-0770","article-title":"Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany","volume":"90","author":"Augustin","year":"2010","journal-title":"Acta Derm Venereol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"adv00579","DOI":"10.2340\/actadv.v101.351","article-title":"Predictors of response to biologics in patients with moderate-to-severe psoriasis: a Danish Nationwide cohort study","volume":"101","author":"Schwarz","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1111\/jdv.17520","article-title":"Effect of baseline disease severity on achievement of treatment target with Apremilast: results from a pooled analysis","volume":"35","author":"Reich","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1517\/13543784.2013.806483","article-title":"Il-17 targeted therapies for psoriasis","volume":"22","author":"Chiricozzi","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1111\/j.1468-3083.2011.04065.x","article-title":"Obesity and psoriasis: body weight and body mass index influence the response to biological treatment","volume":"25","author":"Puig","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"e22892","DOI":"10.7759\/cureus.22892","article-title":"Psoriasis in Saudi population: gender differences in clinical characteristics and quality of life","volume":"14","author":"Alamri","year":"2022","journal-title":"Cureus"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1093\/ced\/llae286","article-title":"High socioeconomic status is significantly associated with psoriasis: results from a cross-sectional, population-based study of 129 855 patients","volume":"50","author":"Dagan","year":"2025","journal-title":"Clin Exp Dermatol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2147\/PTT.S544568","article-title":"Evaluating the role of disease duration in systemic therapy response among patients with moderate-to-severe psoriasis","volume":"15","author":"Dai","year":"2025","journal-title":"Psoriasis"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1177\/24755303221099848","article-title":"Sex differences in moderate to severe psoriasis: analysis of the psoriasis longitudinal assessment and registry","volume":"7","author":"Goldburg","year":"2022","journal-title":"J Psoriasis Psoriatic Arthritis"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jdin.2021.02.003","article-title":"Societal impact for patients with psoriasis: a Nationwide Swedish register study","volume":"3","author":"Habel","year":"2021","journal-title":"JAAD Int"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1186\/s13293-026-00840-w","article-title":"Sex differences in disease severity and immune responses in murine and human inflammatory arthritis","author":"Hemshekhar","year":"2026","journal-title":"Biol Sex Differ"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.ijwd.2020.10.003","article-title":"Gender disparity in dermatologic society leadership: a global perspective","volume":"7","author":"Karol","year":"2021","journal-title":"Int J Womens Dermatol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"337","DOI":"10.23736\/S2784-8671.25.08147-2","article-title":"Gender perspective in the Management of Psoriasis","volume":"160","author":"Maurelli","year":"2025","journal-title":"Ital J Dermatol Venerol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"e745","DOI":"10.1016\/S2589-7500(21)00208-9","article-title":"The false hope of current approaches to explainable artificial intelligence in health care","volume":"3","author":"Ghassemi","year":"2021","journal-title":"Lancet Digit Health"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1562558","DOI":"10.3389\/fmed.2025.1562558","article-title":"Proteomic alterations in ovarian cancer-predicting residual disease status using artificial intelligence and shap-based biomarker interpretation","volume":"12","author":"Yasar","year":"2025","journal-title":"Front Med"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1111\/jdv.19236","article-title":"Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response'): week 28 results from the ongoing phase Iiib randomized, double-blind, parallel-group, guide study","volume":"37","author":"Schakel","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1764025\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T12:41:01Z","timestamp":1772196061000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1764025\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":34,"alternative-id":["10.3389\/fmed.2026.1764025"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1764025","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"article-number":"1764025"}}